每(mei)經(jing)AI快(kuai)訊，未(wei)名醫(yi)藥晚(wan)間公(gong)(gong)(gong)(gong)告，公(gong)(gong)(gong)(gong)司(si)董事會審議(yi)通過議(yi)案，同意(yi)全資(zi)子(zi)公(gong)(gong)(gong)(gong)司(si)山東(dong)衍(yan)(yan)渡生物科(ke)技(ji)(ji)有(you)限公(gong)(gong)(gong)(gong)司(si)（簡稱(cheng)“山東(dong)衍(yan)(yan)渡”）就擬(ni)開(kai)展的(de)重(zhong)組人神(shen)經(jing)生長因子(zi)滴(di)眼液(ye)III期臨床(chuang)試(shi)(shi)驗(yan)研究與天津開(kai)心(xin)生活(huo)科(ke)技(ji)(ji)有(you)限公(gong)(gong)(gong)(gong)司(si)（簡稱(cheng)“開(kai)心(xin)生活(huo)”）簽(qian)署《藥物臨床(chuang)試(shi)(shi)驗(yan)技(ji)(ji)術服務協(xie)議(yi)》，聘請開(kai)心(xin)生活(huo)提供(gong)臨床(chuang)試(shi)(shi)驗(yan)技(ji)(ji)術服務。臨床(chuang)試(shi)(shi)驗(yan)服務費用(yong)(yong)共計5581.76萬(wan)元。未(wei)名醫(yi)藥同日公(gong)(gong)(gong)(gong)告，公(gong)(gong)(gong)(gong)司(si)擬(ni)使用(yong)(yong)自有(you)資(zi)金(jin)對(dui)山東(dong)衍(yan)(yan)渡增(zeng)資(zi)2.9億(yi)元，其中2.9億(yi)元計入注冊資(zi)本(ben)，0元計入資(zi)本(ben)公(gong)(gong)(gong)(gong)積，增(zeng)資(zi)完成后山東(dong)衍(yan)(yan)渡注冊資(zi)本(ben)將增(zeng)至3億(yi)元，仍為公(gong)(gong)(gong)(gong)司(si)全資(zi)子(zi)公(gong)(gong)(gong)(gong)司(si)。